drugset / Trial / NCT02435342
A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis
RandomizedParallel-groupDouble-blind
Summary
The primary purpose of this study is to examine safety outcomes in active plaque psoriasis patients after systemic administration of dalazatide. Clinical outcome measures will also be assessed.
Timeline
- Start
- 2014-10
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dalazatide | Protein / enzyme biologic | 30 ug | Subcutaneous |
| Subject | dalazatide | Protein / enzyme biologic | 60 ug | Subcutaneous |